drugset / Trial / NCT02526420
Versartis International Trial in Adults With Long-Acting Growth Hormone
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A Phase 2, open-label dose-finding safety study of individualized monthly VRS-317 dosing for five months in adults with GHD.
Timeline
- Start
- 2015-07
- Primary completion
- 2016-10
- Completion
- 2016-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Somavaratan | Protein / enzyme biologic | — | Subcutaneous |